Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

A J Davies

首页> 外文期刊>Oncogene >Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

【24h】

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

机译：B细胞淋巴瘤的放射免疫疗法：Y90 ibritumomab tiuxetan和I131 Tositumomab

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing – Y90 ibritumomab tiuxetan and I131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.

机译：B细胞淋巴瘤中以CD20抗原为靶点的放射免疫疗法在过去15年中已明确证明其疗效和耐受性。因此，有两种产品已获得美国食品药品监督管理局的批准销售：Y90 ibritumomab tiuxetan和I131 tositumomab，分别称为Zevalin和Bexxar治疗方案。在复发/难治性疾病中，两者均显示出高应答率和缓解的持久性。关于它们作为初始疗法的效用的数据正在出现，此外，还对其进行了研究，以便与化疗相继使用，并用于清髓性治疗。然而，到目前为止，如何在临床疾病过程中最佳使用这些药物仍是不确定的。

著录项

来源
《Oncogene》 |2007年第25期|共15页
作者
A J Davies;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab. [J] . K Sj?green-Gleisner, Y K Dewaraja, C Chiesa, The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical . 2011,第2期

机译：[（90）Y] ibritumomab tiuxetan或[（131）I] tositumomab治疗的B细胞淋巴瘤患者的剂量测定。
2. Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma [J] . Kohei Hanaoka, Makoto Hosono, Yoichi Tatsumi, EJNMMI Research . 2015,第4期

机译：与B细胞非霍奇金淋巴瘤的放射免疫疗法的治疗反应相关联的Intratumoral 111 in-Ibritumomab Tiuxetan和 18-sup> f-F-FDG分布的异质性
3. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma [J] . WitzigT.E., WisemanG.A., MaurerM.J., American Journal of Hematology . 2013,第7期

机译：免疫刺激性CpG 7909寡聚脱氧核苷酸和90钇伊波单抗tiuxetan放射免疫疗法治疗复发性B细胞非霍奇金淋巴瘤的I期试验
4. Expression profile of HIP1R in B-cell subsets and in silico prediction of its functions in diffuse large B-cell lymphoma [C] . Kah Keng Wong, Alison H Banham International Conference on Intelligent Informatics and Biomedical Sciences . 2018

机译：HIP1R在B细胞亚群中的表达特征及其在弥漫性大B细胞淋巴瘤中的功能的计算机预测
5. Epigenetic regulation of B-cell transcription factors during germinal center B-cell maturation and their silencing in Hodgkin lymphoma. [D] . Ramachandrareddy, Himabindu. 2012

机译：霍奇金淋巴瘤生发中心B细胞成熟过程中B细胞转录因子的表观遗传调控及其沉默。
6. Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab [O] . Sébastien Baechler, Robert F. Hobbs, Heather A. Jacene, -1

机译：预测接受90Y-依妥珠单抗Tiuxetan或131I-Tositumomab放射免疫治疗的患者的血液学毒性
7. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab [O] . A J Davies 2007

机译：B细胞淋巴瘤的放射免疫疗法：Y90 Ibritumomab Tiuxetan和I131 Toshosomab

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

摘要

著录项

相似文献

相关主题

期刊订阅